BridgePoint taps Harrington as CEO

Minneapolis-based BridgePoint Medical has named Denis Harrington as its president and CEO. Harrington most recently spent seven years as the head of U.S. sales for Boston Scientific's Cardiovascular and CRM businesses.

"Denis brings outstanding sales and marketing leadership in interventional vascular therapies to BridgePoint Medical," says Chad Kugler, company co-founder and previous president and general manager, in a statement. "As we enter a new phase for the company I am confident that his expertise will enable our continued growth and ability to serve our customers and their patients successfully." Kugler will remain at BridgePoint as the new COO.

According to its website, BridgePoint develops technology in the field of interventional cardiology for access to and treatment of chronic total occlusions. The company's CrossBoss CTO catheter and their Stingray CTO re-entry system are under investigation and may improve physician access to chronic total occlusions.

BridgePoint recently announced it had completed its third round of financing earlier this year, totaling $9.1 million. The round was lead by a new strategic investor and joined by existing investors New Enterprise Associates, Polaris Venture Partners, Foundation Medical Partners and Michael Berman. 

- get the BridgePoint statement

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.